Flash Finance

Supriya Lifescience LimitedSUPRIYACorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹886.00
MCap ₹7,131 Cr · P/E 36.0
Supriya Lifescience Limited — Stock analysis & AI research Supriya Lifescience Limited — Seasonality — best & worst months Supriya Lifescience Limited — Technical indicators & charts Supriya Lifescience Limited — Technical setup — score, trend, support & resistance Supriya Lifescience Limited — Live exchange announcements
📋 High ROCE Stocks📋 High Operating Margin Stocks📋 High Interest Coverage Stocks📋 High Profit Growth Stocks📋 Low Debt Stocks📋 High Promoter Holding Stocks 📈 Volume Dry-Up Stocks📈 Multi-Timeframe Bullish Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹190 Cr
Sales · Jun 2026
+30.8% YoY
₹47 Cr
Operating Profit · Jun 2026
-8.2% YoY
25.0%
OPM % · Jun 2026
-29.8% YoY
₹24 Cr
Net Profit · Jun 2026
-30.9% YoY
₹2.99
EPS · Jun 2026
-30.8% YoY

📝 Supriya Lifescience Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Supriya Lifescience Limited reported revenue of ₹190 crore for the quarter ended June 2026 (Q1 FY27), up 30.8% from ₹145 crore in the same quarter last year, and down 31.5% sequentially over the March 2026 quarter.

Net profit fell 30.9% year-on-year to ₹24 crore, from ₹35 crore. Earnings per share (EPS) came in at ₹2.99.

Operating profit stood at ₹47 crore — an operating margin (OPM) of 25.0%, compared with 35.6% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Supriya Lifescience Limited posted revenue of ₹828 crore, a growth of 18.9% over FY25, with a net profit of ₹209 crore (up 11.1% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹873 crore with a net profit of ₹198 crore.

Valuation snapshot

At the current price of ₹886.00, SUPRIYA has a market capitalisation of ₹7,131 crore and a trailing P/E of about 36.0.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 5th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 68.30%, foreign institutional investors (FIIs) 6.44%, domestic institutional investors (DIIs) 5.47%, public shareholders 19.79% of Supriya Lifescience Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹7,131 Cr
Current Price ?
₹886.0
P/E ?
35.99below ind
Industry P/E ?
37.20
P/B ?
5.95
P/S ?
8.17
P/FCF ?
3,565.39
Enterprise Value ?
₹7,136 Cr
EV/EBITDA ?
24.59
PEG ?
1.09
Earnings Yield ?
3.6%
Dividend Yield ?
0.12%
Profitability & Returns
Sales (TTM) ?
₹873 Cr
OPM ?
33.2%
Profit after tax (TTM) ?
₹198 Cr
EPS (TTM) ?
₹24.62
ROCE ?
25.0%
ROE ?
16.5%
ROA ?
14.6%
Growth
Sales — latest qtr ?
₹190 Cr
PAT — latest qtr ?
₹24 Cr
YoY qtr sales growth ?
30.8%
YoY qtr profit growth ?
-30.9%
Sales growth (3y) ?
22%
Sales growth (5y) ?
16%
Profit growth (3y) ?
33%
Profit growth (5y) ?
11%
Financial Health
Debt ?
₹5 Cr
Debt to Equity ?
0.00
Interest Coverage ?
188.1
Current Ratio ?
N/A
Ownership
Promoter holding ?
68.30%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
6.9%
Return 6 months ?
38.8%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 105142132140140158161166186184145200206277190 +30.8% -31.5%
Operating Profit 145544324156636566685273729847 -8.2% -51.6%
Other Income 323232232333333 -1.0% -11.7%
Interest 111001001010000 -27.0% —
Depreciation 334444555667789 +38.6% +11.7%
Profit Before Tax 135343304053606263644768679241 -14.0% -55.7%
Net Profit 103829243037454647503550507424 -30.9% -67.5%
EPS 1.184.753.542.973.704.595.545.715.826.294.326.276.179.222.99 -30.8% -67.6%
OPM % 13.4% 38.7% 33.7% 22.7% 29.6% 35.1% 38.9% 39.0% 35.5% 36.7% 35.6% 36.4% 34.9% 35.4% 25.0% -29.8% -29.4%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹696 Cr ₹828 Cr ₹873 Cr +18.9%
Operating Profit ₹261 Cr ₹294 Cr ₹290 Cr +12.9%
OPM % 37.44% 35.54% 33.24% -5.1%
NPM % 26.99% 25.22% 22.70% -6.6%
Other Income ₹10 Cr ₹11 Cr ₹11 Cr +12.2%
Depreciation ₹20 Cr ₹28 Cr ₹30 Cr +36.5%
Interest ₹2 Cr ₹1 Cr ₹1 Cr -16.0%
EBIT ₹240 Cr ₹267 Cr ₹260 Cr +10.9%
PBT ₹248 Cr ₹275 Cr ₹268 Cr +10.5%
Tax ₹61 Cr ₹48 Cr ₹52 Cr -21.1%
Net Profit ₹188 Cr ₹209 Cr ₹198 Cr +11.1%
EPS ₹23.36 ₹25.98 ₹24.65 +11.2%
Material Cost ₹232 Cr ₹182 Cr ₹247 Cr -21.8%
Employee Cost ₹81 Cr ₹72 Cr ₹78 Cr -10.8%
Extraordinary Items — ₹-0 Cr ₹-0 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 16161616 +0.0%
Reserves 6837999811,182 +20.5%
Borrowings 22555 +0.0%
Other Liabilities 98101110154 +40.0%
Total Liabilities 8209211,1121,357 +22.0%
Fixed Assets 262310453689 +52.1%
CWIP 6814914836 -75.7%
Investments 25646399 +57.1%
Other Assets 466399448534 +19.2%
Total Assets 8209211,1121,357 +22.0%

💧 Cash Flow (latest 4 periods)

Metric Mar 2022Mar 2023Mar 2024Mar 2025 % Chg
Cash from Operating Activity 4964113165 +46.0%
Cash from Investing Activity -60-124-174-152 +12.6%
Cash from Financing Activity 150-10-22-8 +63.6%
Net Cash Flow 139-70-834 +104.8%
Free Cash Flow -11-44-322 +106.2%
CFO/OP 51%73%86%86% +0.0%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 67717097 +38.6%
Inventory Days 234140205229 +11.7%
Days Payable 13098129159 +23.3%
Cash Conversion Cycle 171114146167 +14.4%
Working Capital Days 168157144147 +2.1%
ROCE % 19%22%27%25% -7.4%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 68.30%68.30%68.30%68.30%68.30%68.30% +0.0%
FIIs 6.78%5.46%5.19%5.16%6.19%6.44% +4.0%
DIIs 4.86%5.22%5.00%5.70%5.30%5.47% +3.2%
Public 20.08%21.02%21.49%20.83%20.21%19.79% -2.1%
No. of Shareholders 91,92887,91285,09981,16182,08278,561 -4.3%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Supriya Lifescience Limited's revenue in Q1 FY27?
Supriya Lifescience Limited reported revenue of ₹190 crore for the quarter ended June 2026 (Q1 FY27), up 30.8% from ₹145 crore in the same quarter last year, and down 31.5% sequentially over the March 2026 quarter.
What was Supriya Lifescience Limited's net profit in Q1 FY27?
Net profit fell 30.9% year-on-year to ₹24 crore, from ₹35 crore. Earnings per share (EPS) came in at ₹2.99.
What is SUPRIYA's market capitalisation and P/E ratio?
At the current price of ₹886.00, SUPRIYA has a market capitalisation of ₹7,131 crore and a trailing P/E of about 36.0.
Who owns Supriya Lifescience Limited? (shareholding pattern)
As of Sep 2026, promoters held 68.30%, foreign institutional investors (FIIs) 6.44%, domestic institutional investors (DIIs) 5.47%, public shareholders 19.79% of Supriya Lifescience Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI